AR058193A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- AR058193A1 AR058193A1 ARP060105041A ARP060105041A AR058193A1 AR 058193 A1 AR058193 A1 AR 058193A1 AR P060105041 A ARP060105041 A AR P060105041A AR P060105041 A ARP060105041 A AR P060105041A AR 058193 A1 AR058193 A1 AR 058193A1
- Authority
- AR
- Argentina
- Prior art keywords
- otic
- pharmaceutically acceptable
- administration
- buprenorphine
- animal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se revela un método para proveer analgesia sistémica a gatos, perros y otros mamíferos pequenos mediante la administracion otica o transdérmica de opioides. También se revelan composiciones para utilizar en dicho método. Reivindicacion 1: Una composicion farmacéuticamente aceptable para la administracion otica a un animal que comprende buprenorfina, un sistema portador farmacéuticamente aceptable que comprende un solvente que consiste en una fase acuosa y en una fase orgánica, y al menos un agente mejorador de la penetracion. Reivindicacion 20: Uso de la composicion farmacéuticamente aceptable de la reivindicacion 1, caracterizado porque es para la manufactura de un medicamento util para introducir analgesia en un animal mediante la administracion por vía otica e buprenorfina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73852405P | 2005-11-21 | 2005-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058193A1 true AR058193A1 (es) | 2008-01-23 |
Family
ID=37745944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105041A AR058193A1 (es) | 2005-11-21 | 2006-11-16 | Composiciones farmaceuticas |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070116730A1 (es) |
EP (2) | EP1951240A2 (es) |
JP (2) | JP2009516687A (es) |
KR (1) | KR20080071185A (es) |
CN (1) | CN101312730A (es) |
AR (1) | AR058193A1 (es) |
AU (1) | AU2006316607A1 (es) |
BR (1) | BRPI0618891A2 (es) |
CA (2) | CA2629560A1 (es) |
EC (1) | ECSP088461A (es) |
NO (1) | NO20082833L (es) |
NZ (1) | NZ568313A (es) |
PE (1) | PE20070643A1 (es) |
RU (1) | RU2008124805A (es) |
TW (1) | TW200738240A (es) |
WO (2) | WO2007061828A2 (es) |
ZA (2) | ZA200804305B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2522343A1 (en) * | 2006-03-28 | 2012-11-14 | Javelin Pharmaceuticals, Inc. | Formulations of Low Dose Diclofenac and Beta-Cyclodextrin |
MX2008012496A (es) * | 2006-03-28 | 2009-01-07 | Javelin Pharmaceuticals Inc | Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina. |
GB2461681A (en) * | 2008-04-17 | 2010-01-13 | Pharmasol Ltd | Buprenorphine liquid spray formulation with solvent and antioxidant |
PE20081406A1 (es) * | 2006-12-20 | 2008-10-17 | Schering Plough Ltd | Composiciones farmaceuticas de flunixina |
US20090118262A1 (en) * | 2007-11-01 | 2009-05-07 | Rohrs Brian R | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery |
US20110105480A1 (en) * | 2008-06-24 | 2011-05-05 | Keith Freehauf | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
WO2010072398A2 (en) | 2008-12-22 | 2010-07-01 | Boehringer Ingelheim Limited | Veterinary formulations |
US20120277199A1 (en) * | 2009-10-21 | 2012-11-01 | Otonomy, Inc. | Modulation of Gel Temperature of Poloxamer-Containing Formulations |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
MX2013001870A (es) * | 2010-08-17 | 2013-07-03 | Ohr Pharmaceutical Inc | Formulaciones oftalmicas de escualamina. |
PT2611445T (pt) * | 2010-09-03 | 2018-10-24 | Zoetis Belgium S A | Composições de buprenorfina de dose elevada e utilização como analgésico |
EP3363439A3 (en) | 2010-10-25 | 2018-12-05 | University Of Manitoba | Therapeutic compositions for diabetic symmetrical polyneuropathy |
WO2013070656A1 (en) * | 2011-11-07 | 2013-05-16 | Navinta Llc | Sustained release suspension preparation for dextromethorphan |
US11213500B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US10813897B2 (en) | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9962391B2 (en) | 2011-12-27 | 2018-05-08 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9468599B2 (en) | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213501B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
WO2014160702A1 (en) * | 2013-03-25 | 2014-10-02 | Chs Pharma, Inc. | Retinopathy treatment |
BR112015025684A2 (pt) * | 2013-04-08 | 2017-07-18 | Indivior Uk Ltd | método para proporcionar um ou mais opióide(s) a um indivíduo, forma de dosagem, método para tratar ou prevenir dor e método para tratar ou prevenir dependência ou vício |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
ES2808150T3 (es) | 2014-11-07 | 2021-02-25 | Indivior Uk Ltd | Regímenes de dosificación de buprenorfina |
EP3368013B1 (en) * | 2015-10-27 | 2023-11-08 | Benuvia Therapeutics, LLC | Liquid buprenorphine formulations |
CN109789137B (zh) * | 2016-09-13 | 2023-01-13 | 昱展新药生技股份有限公司 | 丁丙诺啡缓释制剂 |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
GB201716830D0 (en) | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
WO2019076997A1 (en) | 2017-10-20 | 2019-04-25 | Chiesi Farmaceutici S.P.A. | PHARMACEUTICAL FORMULATIONS COMPRISING AN OPIOID RECEPTOR AGONIST AS ACTIVE SUBSTANCES, METHODS OF MAKING THEM AND THERAPEUTIC USES THEREOF |
US11419866B2 (en) * | 2018-01-22 | 2022-08-23 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition for sustained release delivery of buprenorphine |
WO2023056043A1 (en) * | 2021-09-30 | 2023-04-06 | Elanco Us Inc. | Stable formulations of buprenorphine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8533582A (en) * | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US6384043B1 (en) * | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
CZ306398A3 (cs) * | 1996-03-25 | 1999-01-13 | Lts Lohmann Therapie-Systeme Gmbh | Transdermální terapeutický systém s malou tloušťkou a vysokou flexibilitou a způsob jeho výroby |
US6004969A (en) * | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
IT1302682B1 (it) * | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
WO2000072835A2 (en) * | 1999-05-27 | 2000-12-07 | El Khoury George F | Topical application of muscarinic and opioid agents for treatment of tinnitus |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
WO2002005647A1 (en) * | 2000-07-13 | 2002-01-24 | Euro-Celtique, S.A. | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
US20040258740A1 (en) * | 2003-04-10 | 2004-12-23 | Nene Labs | Transdermal delivery composition |
-
2006
- 2006-11-16 PE PE2006001462A patent/PE20070643A1/es not_active Application Discontinuation
- 2006-11-16 EP EP06837885A patent/EP1951240A2/en not_active Withdrawn
- 2006-11-16 CN CNA2006800434521A patent/CN101312730A/zh active Pending
- 2006-11-16 RU RU2008124805/15A patent/RU2008124805A/ru not_active Application Discontinuation
- 2006-11-16 NZ NZ568313A patent/NZ568313A/en not_active IP Right Cessation
- 2006-11-16 AU AU2006316607A patent/AU2006316607A1/en not_active Abandoned
- 2006-11-16 AR ARP060105041A patent/AR058193A1/es not_active Application Discontinuation
- 2006-11-16 CA CA002629560A patent/CA2629560A1/en not_active Abandoned
- 2006-11-16 WO PCT/US2006/044640 patent/WO2007061828A2/en active Application Filing
- 2006-11-16 US US11/600,418 patent/US20070116730A1/en not_active Abandoned
- 2006-11-16 BR BRPI0618891-5A patent/BRPI0618891A2/pt not_active IP Right Cessation
- 2006-11-16 KR KR1020087014861A patent/KR20080071185A/ko not_active Application Discontinuation
- 2006-11-16 US US11/600,560 patent/US20070117828A1/en not_active Abandoned
- 2006-11-16 EP EP06844380A patent/EP1954275A2/en not_active Withdrawn
- 2006-11-16 WO PCT/US2006/044464 patent/WO2007061739A2/en active Application Filing
- 2006-11-16 JP JP2008541364A patent/JP2009516687A/ja active Pending
- 2006-11-16 CA CA002630072A patent/CA2630072A1/en not_active Abandoned
- 2006-11-16 JP JP2008541335A patent/JP2009516686A/ja not_active Withdrawn
- 2006-11-17 TW TW095142635A patent/TW200738240A/zh unknown
-
2008
- 2008-05-19 EC EC2008008461A patent/ECSP088461A/es unknown
- 2008-05-19 ZA ZA200804305A patent/ZA200804305B/xx unknown
- 2008-05-20 ZA ZA200804355A patent/ZA200804355B/xx unknown
- 2008-06-20 NO NO20082833A patent/NO20082833L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200804355B (en) | 2009-04-29 |
ECSP088461A (es) | 2008-06-30 |
WO2007061828A2 (en) | 2007-05-31 |
JP2009516687A (ja) | 2009-04-23 |
BRPI0618891A2 (pt) | 2011-09-13 |
AU2006316607A1 (en) | 2007-05-31 |
CA2630072A1 (en) | 2007-05-31 |
TW200738240A (en) | 2007-10-16 |
KR20080071185A (ko) | 2008-08-01 |
WO2007061828A3 (en) | 2007-07-19 |
ZA200804305B (en) | 2009-04-29 |
US20070116730A1 (en) | 2007-05-24 |
EP1954275A2 (en) | 2008-08-13 |
EP1951240A2 (en) | 2008-08-06 |
RU2008124805A (ru) | 2009-12-27 |
CA2629560A1 (en) | 2007-05-31 |
CN101312730A (zh) | 2008-11-26 |
JP2009516686A (ja) | 2009-04-23 |
WO2007061739A2 (en) | 2007-05-31 |
WO2007061739A3 (en) | 2007-07-12 |
NZ568313A (en) | 2011-11-25 |
PE20070643A1 (es) | 2007-08-10 |
US20070117828A1 (en) | 2007-05-24 |
NO20082833L (no) | 2008-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058193A1 (es) | Composiciones farmaceuticas | |
PE20081297A1 (es) | Forma de dosificacion transdermica resistente a la manipulacion | |
BRPI0819235A2 (pt) | Sistema de distribuição transdérmica para hormônios e esteróides | |
ECSP088670A (es) | Sistema de administracion de plaguicidas | |
AR048017A1 (es) | Composicion y metodo para aumentar la biodisponibilidad | |
BRPI0921687A8 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
BRPI0412975A (pt) | espuma penetrante para uso farmacêutico | |
AR027065A1 (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
BRPI0510909A2 (pt) | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor | |
BRPI0822162B8 (pt) | composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal | |
CL2003002277A1 (es) | Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente. | |
BRPI0414000A (pt) | composição farmacêutica sólida, forma de dosagem, uso da composição farmacêutica, e, método para a preparação da composição | |
ECSP13013087A (es) | Compuestos para el tratamiento de la adicción | |
CL2007003331A1 (es) | Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente. | |
CL2011000044A1 (es) | Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria. | |
AR067751A1 (es) | Composicion veterinaria topica, proceso para la preparacion de una composicion y metodo para el tratamiento de infeccion endoparasitaria o infestacion en un animal homeotermico | |
PE20081874A1 (es) | Composicion farmaceutica que comprende buprenorfina y naloxona | |
CL2009001080A1 (es) | Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo. | |
CY1114311T1 (el) | Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης | |
CO5050328A1 (es) | Sistema solvente para la mejor penetracion de compuestos farmaceuticos | |
WO2010019611A3 (en) | Bridged polycyclic compound based compositions for topical and oral applications | |
RS106704A (en) | Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same | |
BRPI0506630A (pt) | composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada | |
AR064104A1 (es) | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas | |
AR064185A1 (es) | Composiciones y metodos para tratar las convulsiones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |